Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

    Results: 1 to 20 of 452

    1.

    An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer.

    Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C.

    Genome Biol. 2007;8(8):R157.

    PMID:
    17683518
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    2.

    Identification of subtypes in human epidermal growth factor receptor 2--positive breast cancer reveals a gene signature prognostic of outcome.

    Staaf J, Ringnér M, Vallon-Christersson J, Jönsson G, Bendahl PO, Holm K, Arason A, Gunnarsson H, Hegardt C, Agnarsson BA, Luts L, Grabau D, Fernö M, Malmström PO, Johannsson OT, Loman N, Barkardottir RB, Borg A.

    J Clin Oncol. 2010 Apr 10;28(11):1813-20. Epub 2010 Mar 15.

    PMID:
    20231686
    [PubMed - indexed for MEDLINE]
    3.

    T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers.

    Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, Solbach C, Hanker L, Ahr A, Metzler D, Engels K, Karn T, Kaufmann M.

    Breast Cancer Res. 2009;11(2):R15. Epub 2009 Mar 9.

    PMID:
    19272155
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    4.

    Prognostic breast cancer signature identified from 3D culture model accurately predicts clinical outcome across independent datasets.

    Martin KJ, Patrick DR, Bissell MJ, Fournier MV.

    PLoS One. 2008 Aug 20;3(8):e2994.

    PMID:
    18714348
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    5.

    Meta-analysis and gene set enrichment relative to er status reveal elevated activity of MYC and E2F in the "basal" breast cancer subgroup.

    Alles MC, Gardiner-Garden M, Nott DJ, Wang Y, Foekens JA, Sutherland RL, Musgrove EA, Ormandy CJ.

    PLoS One. 2009;4(3):e4710. Epub 2009 Mar 9.

    PMID:
    19270750
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    6.

    Estrogen receptor and HER2/neu status affect epigenetic differences of tumor-related genes in primary breast tumors.

    Sunami E, Shinozaki M, Sim MS, Nguyen SL, Vu AT, Giuliano AE, Hoon DS.

    Breast Cancer Res. 2008;10(3):R46. Epub 2008 May 16.

    PMID:
    18485221
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    7.

    Forkhead box A1 expression in breast cancer is associated with luminal subtype and good prognosis.

    Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, Badve S.

    J Clin Pathol. 2008 Mar;61(3):327-32. Epub 2007 Nov 23.

    PMID:
    18037662
    [PubMed - indexed for MEDLINE]
    9.

    Meta-analysis of breast cancer microarray studies in conjunction with conserved cis-elements suggest patterns for coordinate regulation.

    Smith DD, Saetrom P, Snøve O Jr, Lundberg C, Rivas GE, Glackin C, Larson GP.

    BMC Bioinformatics. 2008 Jan 28;9:63.

    PMID:
    18226260
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    10.

    Challenges in projecting clustering results across gene expression-profiling datasets.

    Lusa L, McShane LM, Reid JF, De Cecco L, Ambrogi F, Biganzoli E, Gariboldi M, Pierotti MA.

    J Natl Cancer Inst. 2007 Nov 21;99(22):1715-23. Epub 2007 Nov 13.

    PMID:
    18000217
    [PubMed - indexed for MEDLINE]
    Free Article
    11.

    Biological processes associated with breast cancer clinical outcome depend on the molecular subtypes.

    Desmedt C, Haibe-Kains B, Wirapati P, Buyse M, Larsimont D, Bontempi G, Delorenzi M, Piccart M, Sotiriou C.

    Clin Cancer Res. 2008 Aug 15;14(16):5158-65.

    PMID:
    18698033
    [PubMed - indexed for MEDLINE]
    Free Article
    12.

    Aging impacts transcriptomes but not genomes of hormone-dependent breast cancers.

    Yau C, Fedele V, Roydasgupta R, Fridlyand J, Hubbard A, Gray JW, Chew K, Dairkee SH, Moore DH, Schittulli F, Tommasi S, Paradiso A, Albertson DG, Benz CC.

    Breast Cancer Res. 2007;9(5):R59.

    PMID:
    17850661
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    13.

    Low expression of a few genes indicates good prognosis in estrogen receptor positive breast cancer.

    Buechler S.

    BMC Cancer. 2009 Jul 20;9:243.

    PMID:
    19619298
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    14.

    Expression profiling to predict postoperative prognosis for estrogen receptor-negative breast cancers by analysis of 25,344 genes on a cDNA microarray.

    Nagahata T, Onda M, Emi M, Nagai H, Tsumagari K, Fujimoto T, Hirano A, Sato T, Nishikawa K, Akiyama F, Sakamoto G, Kasumi F, Miki Y, Tanaka T, Tsunoda T.

    Cancer Sci. 2004 Mar;95(3):218-25.

    PMID:
    15016320
    [PubMed - indexed for MEDLINE]
    15.

    Redefining prognostic factors for breast cancer: YB-1 is a stronger predictor of relapse and disease-specific survival than estrogen receptor or HER-2 across all tumor subtypes.

    Habibi G, Leung S, Law JH, Gelmon K, Masoudi H, Turbin D, Pollak M, Nielsen TO, Huntsman D, Dunn SE.

    Breast Cancer Res. 2008;10(5):R86. Epub 2008 Oct 16.

    PMID:
    18925950
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    16.

    Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.

    Harigopal M, Heymann J, Ghosh S, Anagnostou V, Camp RL, Rimm DL.

    Breast Cancer Res Treat. 2009 May;115(1):77-85. Epub 2008 Jun 3.

    PMID:
    18521745
    [PubMed - indexed for MEDLINE]
    17.

    GATA-3 expression in breast cancer has a strong association with estrogen receptor but lacks independent prognostic value.

    Voduc D, Cheang M, Nielsen T.

    Cancer Epidemiol Biomarkers Prev. 2008 Feb;17(2):365-73.

    PMID:
    18268121
    [PubMed - indexed for MEDLINE]
    Free Article
    18.

    Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group.

    Kyndi M, Sørensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J; Danish Breast Cancer Cooperative Group.

    J Clin Oncol. 2008 Mar 20;26(9):1419-26. Epub 2008 Feb 19.

    PMID:
    18285604
    [PubMed - indexed for MEDLINE]
    19.

    Overexpression of E2F-5 correlates with a pathological basal phenotype and a worse clinical outcome.

    Umemura S, Shirane M, Takekoshi S, Kusakabe T, Itoh J, Egashira N, Tokuda Y, Mori K, Osamura YR.

    Br J Cancer. 2009 Mar 10;100(5):764-71.

    PMID:
    19259095
    [PubMed - indexed for MEDLINE]
    Free PMC Article
    20.

    Basal-like phenotype is not associated with patient survival in estrogen-receptor-negative breast cancers.

    Jumppanen M, Gruvberger-Saal S, Kauraniemi P, Tanner M, Bendahl PO, Lundin M, Krogh M, Kataja P, Borg A, Fernö M, Isola J.

    Breast Cancer Res. 2007;9(1):R16.

    PMID:
    17263897
    [PubMed - indexed for MEDLINE]
    Free PMC Article

      Display Settings:

      Format
      Items per page
      Sort by

      Send to:

      Choose Destination

      Supplemental Content

      Find related data

      Write to the Help Desk